◆ NeutralRDY
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
The Motley Fool·
Dr. Reddy's Laboratories reported double-digit underlying base business growth in Q2 2027, with Semaglutide supply chain issues resolved and reloading to begin by November 2026. Despite a 1.5% revenue decline due to reduced Lenalidomide sales, strong emerging market demand and a 52.1% gross margin provided stability. The company is advancing its biosimilar pipeline with Abatacept targeting FDA approval in December 2026 and scaling its CDMO segment to $100 million in trailing 12-month revenue.
Read Full Article at The Motley Fool →